Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies

OBJECTIVES: To define a series of clinical trial transparency measures and apply them to large pharmaceutical and biotechnology companies and their 2014 FDA-approved drugs. DESIGN: Cross-sectional descriptive analysis of all clinical trials supporting 2014 Food and Drugs Administration (FDA)-approve...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Jennifer E, Wilenzick, Marc, Ritcey, Nolan, Ross, Joseph S, Mello, Michelle M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Ethics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728266/
https://www.ncbi.nlm.nih.gov/pubmed/29208616
http://dx.doi.org/10.1136/bmjopen-2017-017917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728266/
https://www.ncbi.nlm.nih.gov/pubmed/29208616
http://dx.doi.org/10.1136/bmjopen-2017-017917

Ejemplares similares